Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Abstract 5776: Integrative analysis of regional MRI phenotypes in high-grade glioma: Dimensional reduction of multi-omics imaging and molecular profiles
Kenaston, Matthew W. , Flick, Matthew , Tran, Nhan L. , Hu, Leland , Tran, Nhan L , Kannan, Kasthuri S. , Ceccarelli, Michele

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5776-5776

10.1158/1538-7445.am2025-5776 Get It

Abstract Introduction: High-grade gliomas (HGG) are aggressive brain tumors with heterogeneous cell populations, including invasive regions driving disease progression and recurrence. Our previous work integrated molecular profiling with spatially matched advanced multiparametric MRI in a cohort of HGG patients with multi-regional sampling, uncovering distinct biological signatures linked to individual advanced MRI phenotypes. Yet, the relationships between MRI phenotypes—and how this potentially informs underlying biology—remains unexplored. Here, we leverage an unsupervised approach to dimensional reduction for a broad array of MRI features and compare regional transcriptomic signatures in a cohort of image-localized HGG samples. Methods: From our existing data, we selected 20 HGG patients with 73 multi-regional tumor biopsies, each including 18 advanced MRI parameter calculations. With an iterative approach, data was projected using uniform manifold approximation (UMAP) at multiple resolutions and clustered, producing high-confidence stable clusters. We used random forest modeling to assess cluster associations with previously identified signatures. Cluster-specific transcriptomic profiles were detected by DESeq2 and subsequent gene-set enrichment analysis. We further evaluated Pearson correlations and statistical fit with MRI image parameters by performing pathway analysis on genes with significant correlations by image feature, across clusters. Results: 8 clusters emerged from our analyses. Most advanced MRI features exhibited statistically significant differences across clusters, forming unique patterns of feature behavior. Notably, while these image-based clusters did not correlate well with metabolic profiles, contrast enhancement, or genomics, they did demonstrate distinct and HGG-relevant transcriptomic profiles, with shared and divergent signatures. Across clusters, we also identified several correlations between specific MRI parameters and gene pathway trends. These highlighted combined patterns of multiple MRI features, offering a spectrum of regional phenotypes imperceptible with single feature analysis. We generalize these results to an image-based decision matrix to detect biologic signatures for validation. Conclusion: Our integrative analysis of MRI mapping stratifies imaged-based patterns to non-invasively assess molecular signatures within HGG. This approach will help elucidate MRI biomarkers that may predict glioma behavior and support future individualized treatment approaches. Citation Format: Matthew W. Kenaston, Matthew Flick, Kasthuri Kannan, Michele Ceccarelli, Nhan Tran, Leland S. Hu. Integrative analysis of regional MRI phenotypes in high-grade glioma: Dimensional reduction of multi-omics imaging and molecular profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5776.
Abstract 4707: Electrochemotherapy for the treatment of head and neck squamous cell carcinoma
Michinski, Sebastián , Evans, Lorna A. , Lertora, Raquel, Evans, Lorna A , Maglietti, Felipe Horacio

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 4707-4707

10.1158/1538-7445.am2025-4707 Get It

Abstract Squamous cell carcinoma (SCC) is the second most prevalent type of skin cancer after basal cell carcinoma, with the highest incidence occurring in sun-exposed regions of the body, particularly the head and neck. Approximately 300,000 new cases are diagnosed each year, imposing significant financial burdens on healthcare systems due to treatment costs and on the economy due to productivity losses. Surgery remains the primary treatment option; however, patients, particularly those with advanced-stage disease, may decline surgery due to concerns about functional and cosmetic outcomes. Other effective treatments include cryosurgery, radiotherapy, topical therapies, photodynamic therapy, and Mohs micrographic surgery. Recently, electrochemotherapy (ECT) has emerged as a novel treatment option. ECT involves administering bleomycin followed by electric pulses targeted at the tumor and surrounding margins, inducing transient cell membrane permeabilization. This enhances drug uptake and amplifies cytotoxic effects by over 1,000-fold. Since 2006, ECT has been a standard therapy in Europe and was introduced in Argentina in 2020, offering a new approach for patients who are unsuitable for or decline other treatments. In this study, we present outcomes from six patients with head and neck SCC treated with ECT on an outpatient basis. Most patients required only a single 60-minute treatment session. Observed side effects included grade 1-2 edema, pain, and flu-like symptoms per CTCAE 4.0. Tumor response was assessed using RECIST criteria, with results showing 71.4% complete response (5 of 7 lesions), 14.3% partial response (1 lesion), and 14.3% progressive disease, yielding an objective response rate of 85.7%.In conclusion, electrochemotherapy proved to be a safe and effective treatment for select head and neck SCC patients who are not candidates for surgery, providing a promising alternative in the therapeutic landscape. Citation Format: Felipe H. Maglietti, Sebastian D. Michinski, Lorna A. Evans, Raquel Lertora. Electrochemotherapy for the treatment of head and neck squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4707.
Time deficiency: an affliction of healthcare systems and how to ameliorate it
Montori, Víctor M. , Bradley, Stephen H , Montori, Victor M

BMJ Evidence-Based Medicine | April 21, 2025 | Volume: 31 | Issue: 1 | Pages: 71-72

10.1136/bmjebm-2024-113455 | PMID 40258655 Get It

Abstract 5070: Tumor spatial configuration predicts pancreatic cancer recurrence risk after total neoadjuvant therapy
Maraone, Andrea V., Siddiqui, Zafar, Cisneros, Luis , Truty, Mark J. , Fernández-Zapico, Martín E. , Maraone, Andrea V. , Cisneros, Luis H , Garzaro, Andrea V. Maraone , Toruner, Merih Deniz , Thiels, Cornelius A. , McWilliams, Robert R. , Alberts, Steven R. , Graham, Rondell P. , Maley, Carlo C. , Shi, Qian , Carr, Ryan M

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5070-5070

10.1158/1538-7445.am2025-5070 Get It

Abstract Despite advances in surgery and chemotherapy, patients with resectable pancreatic ductal adenocarcinoma (PDAC) face high recurrence rates (40-60%). Total neoadjuvant therapy (TNT) seeks to enhance margin-negative resections (R0) and address micrometastatic disease, with potential survival benefits. Yet, TNT still results in high recurrence rates, with 1-, 2-, and 3-year disease-free survival (DFS) at 65%, 48%, and 32%, respectively. Residual cancer extent is a key prognostic factor in PDAC after TNT. Tumor response scores show favorable outcomes only for patients achieving near-complete or complete pathologic response. In a cohort of 511 PDAC patients treated with TNT and surgery (2015-2022), improved DFS was only found in those with a complete pathologic response (pCR, 7.8%). This highlights the limited use of current response scoring in stratifying post-TNT patient risk, underscoring the need to better understand disease persistence and relapse. Here we developed a quantitative method to assess residual cancer. Using a digital pathology H&E library from 2180 PDAC cases (2000-2022), an AI platform segmented tissue into cancer epithelium, stroma, and normal regions. For 202 TNT-treated cases without pCR, we calculated a ratio of cancer area to stromal area from representative slides. Modeled after the histologic tumor regression grade (HTRG) system, cases were classified into <5%, 5-50%, or >50% cancer-to-stroma ratios. However, this measure alone showed no difference in DFS, suggesting tumor burden cannot fully explain differences in clinical outcomes. We hypothesized that the spatial organization of the tumor microenvironment (TME) is a determinant of patient outcomes. Drawing from landscape ecology, which studies spatial properties of ecosystems, we applied similar principles to analyze tissue architecture. Using an AI-based two-class segmentation of whole-slide images, we assessed spatial features like patch area, perimeter, density, and Shannon diversity. Python’s ‘pylandstats’ package calculated 21 spatial metrics, reduced via stepwise Cox regression using the Akaike information criterion (AIC). The final model included mean Shannon diversity, mean and standard deviation of stromal patch areas, and stromal patch density. Kaplan-Meier analysis of 202 samples stratified model predictions into quartiles, correlating with high (mean DFS 10.85 months), medium (19.32 months), and low risk (25.92 months) groups. These findings aligned with model expectations, underscoring the potential of spatial TME analysis to predict outcomes. Citation Format: Andrea V. Maraone, Zafar Siddiqui, Luis H. Cisneros, Merih D. Toruner, Mark Truty, Cornelius Thiels, Robert R. McWilliams, Steven R. Alberts, Rondell P. Graham, Carlo Maley, Qian Shi, Martin E. Fernandez-Zapico, Ryan M. Carr. Tumor spatial configuration predicts pancreatic cancer recurrence risk after total neoadjuvant therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5070.
Abstract 2531: Novel staining method for visualization, isolation and processing of intracranial brain tumors
Herfindahl-Quint, Anders, Jain, Sonia , Doherty, Caroline Lloyd , Zhang, Wenjuan , Burgenske, Danielle M. , Sarkaria, Jann N.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2531-2531

10.1158/1538-7445.am2025-2531 Get It

Abstract Background and Objective: Glioblastoma (GBM) is most common primary brain tumor with dire need of novel therapeutics. Studies with intracranial tumors are required for robust characterization and development of novel drugs for brain cancer. Tumor harvest and processing is an important aspect to study pharmacokinetics, pharmacodynamics, drug delivery, and tumor evolution. Typically, delineating and dissecting tumor from surrounding brain for varied downstream processes is dependent on the distinct morphology of the tumor and/or expression of fluorescent marker. However, genetic modification of the tumor cells for the expression of fluorescent protein is not always possible, especially for patient-derived xenograft (PDX) tumor models. Thus, we have developed a dye-based staining method to confidently visualize tumor in the brain and assessed usability of isolated tumors for drug and DNA analysis. Methodology: Whole brains were harvested from mice with intracranial Mayo GBM PDX tumors and stored at -80oC freezer. Few days prior to staining, brains were transferred to -20oC freezer. Brain was cut into 1 mm thick coronal sections and transferred onto glass slides. Slices were covered with toluidine blue (TB) solution (0.05 to 10 mg/mL) for 45 s. Excess stain solution was removed, and slices were observed under white light. Regions of tumor became more transparent, while normal brain remained opaque. This enabled dissection of tumor from normal brain for downstream analyses. Results: TB concentration (0.05 to 10 mg/mL) was optimized to stain 1 mm thick sections of fresh frozen brain, and the best contrast between tumor to normal brain was observed at 0.1-0.3 mg/mL. TB aided differential visualization of tumors in several PDX models - GBM12, GBM43, GBM39 and GBM108 - suggesting broad applicability. To evaluate the accuracy of TB staining, brain with PDX tumor transduced with pSINeGFP/fLuc2 was observed by both TB staining and eGFP fluorescence. This analysis demonstrated excellent concordance across 6 animals with three distinct PDX models. Genomic DNA was isolated from tumor dissected under TB guidance and analyzed by PCR for primers specific for murine vs human PTGER2. 50-70% of the DNA in tumor samples was detected to be of human origin while normal brain tissue had 90-95% of the mouse DNA highlighting the specificity of TB stain for tumor detection. Tumors from drug treated GBM108 PDX were isolated under TB guidance and comparable drug levels were detected by LC-MS/MS as analyzed in GFP-assisted tumor samples. Conclusion: Staining fresh frozen thick brain sections with toluidine blue enables visualization of tumor from normal brain regions that is compatible with varied downstream processes. Development of such staining assays can help faster and easier tumor processing and is not dependent on genetic modification of tumor cells prior to experimentation. Citation Format: Sonia Jain, Anders Herfindahl-Quint, Caroline D. Doherty, Wenjuan Zhang, Danielle M. Burgenske, Jann N. Sarkaria. Novel staining method for visualization, isolation and processing of intracranial brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2531.
Abstract 2282: Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity
Williams, Jacob , Jahagirdar, Om , Li, Jingmei, Godbole, Devika , Dorling, Leila , Dennis, Joe, Kushi, Larry, Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Zheng, Wei , Huo, Dezheng , Easton, Douglas F. , Chatterjee, Nilanjan , Kraft, Peter, Wong, W. W., Zhu, Qianqian , Ahearn, Thomas U., Li, James , Zanti, Maria , Jia, Guochong , Hu, Qiang , Brandenburg, Jean‐Tristan , Li, Yàn , Ho, Weang-Kee , Miranda, Patricio , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Martin Jinye , Zhang, Yan , John, Esther M. , Torres-Mejı́a, Gabriela , Kushi, Larry, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Ziv, Elad , Fejerman, Laura , Chatterjee, Nilanjan , García‐Closas, Montserrat , Wong, Wendy, Michailidou, Kyriaki , Dutta, Diptavo , Ahearn, Thomas U. , Zhang, Haoyu

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2282-2282

10.1158/1538-7445.am2025-2282 Get It

Abstract Introduction: Breast cancer genome-wide association studies (GWAS) have identified over 200 susceptibility loci, many replicated in diverse populations. However, cross-ancestry evaluation of breast cancer genetic architecture remains limited. We examined breast cancer genetic architecture using GWAS summary results from European (EUR; cases (ca) = 188,474, controls (co) = 96,201), East Asian (EAS; ca = 20,393, co = 86,329), African American (AA; ca = 9,235, co = 10,184), and US Hispanic/Latina and Latin American (H/L; ca = 2,396, co =7,468) studies. Methods: GWAS results were derived from the Breast Cancer Association Consortium, the African Ancestry Breast Cancer Genetics Consortium (AABCG), Biobank Japan, and a meta-analysis of five studies of H/L women with breast cancer. Linkage disequilibrium (LD) scores were generated for EUR, EAS, and AMR using the 1000 Genomes Project, while AA LD scores were derived from a subset of AABCG controls. Heritability was estimated for each ancestry group using LD score regression. Genetic correlations between populations were assessed via Popcorn. Polygenicity was analyzed using GENESIS; however, due to the limited sample size in the H/L studies, these estimates were restricted to AA, EAS, and EUR. Enrichment of heritability across regulatory elements was evaluated using stratified LD score regression across all populations. Results: The logit-scale heritability and corresponding standard error (SE) were 0.466 (0.066) for EAS, 0.501 (0.050) for EUR, 0.588 (0.360) for H/L, and 0.614 (0.095) for AA. The estimated number of independent susceptibility loci was 4,446 for EAS, 5,235 for EUR, and 8,308 for AA. Using a clumping and thresholding approach, an optimal set of common variants were projected to explain 38.6% (EUR), 39.4% (EAS), and 26.2% (AA) of genetic variance for samples of 100,000 cases and 100,000 controls with AUCs from corresponding estimated polygenic risk scores (PRSs) of 0.621 (EUR), 0.634 (EAS), and 0.611 (AA). Genetic correlations were strongest between EUR and EAS (ρ = 0.79, SE = 0.08) and EUR and H/L (ρ = 0.68, SE = 0.21), and weakest between AA and EAS (ρ = 0.42, SE = 0.14) and AA and H/L (ρ = 0.26, SE = 0.24). Among 73 genomic features, we found significant (P < 0.05/73) enrichment in heritability in EUR for ‘ancient promoter’ regions, transcription factor binding sites, H3K4me3, ‘super-enhancers’, H3K4me1, H3K27ac; in EAS for ‘super-enhancers’; and in AA for H3K27ac. No genomic features were significantly enriched in H/L, likely due to limited power. Conclusion: These findings suggest a shared breast cancer genetic architecture across diverse populations, as well as the potential for a similar level of breast cancer risk stratification by PRS in these populations. Expanding GWAS in underrepresented populations is essential to improve genetic risk predictions and foster equitable cancer prevention. Citation Format: James L. Li, Maria Zanti, Jacob Williams, Om Jahagirdar, Guochong Jia, Qiang Hu, Jean-Tristan Brandenburg, Li Yan, Weang-Kee Ho, Jingmei Li, José P. Miranda, Devika Godbole, Julie-Alexia Dias, Leila Dorling, Wenlong C. Chen, Nicholas Boddicker, Ying Wang, Alicia Martin, Martin J. Zhang, Yan Zhang, Joe Dennis, Esther M. John, Gabriela Torres-Mejia, Larry Kushi, Jeffrey Weitzel, Susan L. Neuhausen, Luis Carvajal-Carmona, Christopher Haiman, Elad Ziv, Laura Fejerman, Wei Zheng, Dezheng Huo, Douglas Easton, Nilanjan Chatterjee, Peter Kraft, Montserrat Garcia-Closas, Wendy Wong, Kyriaki Michailidou, Qianqian Zhu, Diptavo Dutta, Thomas U. Ahearn, Haoyu Zhang. Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2282.
Abstract 4999: Multi-omics insights into the molecular signature and prognosis of hypopharyngeal squamous cell carcinoma
Ren, Yanxin , Feng, Chun , Yu, Dan , Wang, Xiaoyan , Yu, Siting, Zhang, Hongjiang, Huo, Bo , Jiang, Honglu, Li, Zuli, Wang, Junlin , Zhong, Qi , Xiong, Wei, Yang, Qin , Zhang, Hongjiang, Huo, Bangyun, Su, Yu‐Xiong , Yang, Ping , Liao, Yong , Wang, Junwen

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 4999-4999

10.1158/1538-7445.am2025-4999 Get It

Abstract Approximately two-thirds of hypopharyngeal squamous cell carcinoma (HPSCC) are diagnosed in advanced stage, with the worst prognosis among head and neck squamous cell carcinomas (HNSCCs). Identifying biomarkers for high-risk patients who need aggressive treatment is crucial. We present mutational, transcriptomic and proteomic studies of 103 Chinese HPSCC patients, observing a higher prevalence and poorer prognosis in males comparing to females. Genes in estrogen response pathways are up-regulated and proteins phosphorylated by protein kinase C (PKC) and Cyclin-dependent kinases (CDKs) are aberrantly regulated. We identify aberrant copy number regions including SOX2 (3q26.33), FGFR (8p11.23), CCND1 (11q13.3), CDKN2A/2B (9p21.3), and MYC (8q24.21). HPV status combined with highly mutated genes as predictive markers was assessed, including SYNE1 in HPV(-), MUC4 in HPV(+) patients. We confirm the presence of four known gene expression (GE) subtypes of HNSCC in our HPSCC cohort and present the genomic alterations, patient characteristics and survival status of each subtype. A predictive model involving clinical factors and transcriptomic expression of six genes was established and cross-site validated. The findings open new opportunities for stratifying high-risk patients and molecular targets for novel therapeutic strategies. Citation Format: Yanxin Ren, Wei Xiong, Chun Feng, Dan Yu, Xiaoyan Wang, Qing Yang, Siting Yu, Hongjiang Zhang, Bangyun Huo, Honglu Jiang, Zuli Li, Junlin Wang, Yu-Xiong Su, Ping Yang, Yong Liao, Qi Zhong, Junwen Wang. Multi-omics insights into the molecular signature and prognosis of hypopharyngeal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4999.
Abstract 5595: Multiomic profiling identified biomarkers of response to selective Src family kinase inhibition in preclinical models of cholangiocarcinoma
Carlson, Danielle M. , Jessen, Erik , Abeynayake, Aushinie, Werneburg, Nathan W., Li, Binbin , Truty, Mark J. , Kuipers, Hendrien , Carlson, Danielle Marie , Sample, Jack W. , Mun, Dong‐Gi , Tomlinson, Jennifer L. , Abdelrahman, Amro M. , Borad, Mitesh J. , Ilyas, Sumera I. , Gores, Gregory J. , Smoot, Rory L. , Li, B.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5595-5595

10.1158/1538-7445.am2025-5595 Get It

Abstract Introduction: Src Family Kinases (SFKs) have a crucial role in tumor proliferation, survival, and metastasis. NXP900 is a highly selective SFK inhibitor a novel mechanism of action that locks SFKs in a closed, inhibited conformation, preventing interaction with substrate proteins, unlike other SFK inhibitors like dasatinib. A phase 1 study of NXP900 in patients with advanced solid tumors was recently initiated. Our preclinical studies showed therapeutic efficacy of NXP900 in cholangiocarcinoma (CCA) through decreased YAP, RAF-MAP and PI3K-AKT signaling. Here, we examined mechanisms of sensitivity and resistance to SFK inhibition. Methods: Secondary resistance was explored by generating a NXP900-resistant human cell line (HuCCT1-R) via prolonged exposure to NXP900, followed by multiomic profiling. Primary resistance was studied in vivo using nine heterogeneous patient-derived xenograft (PDX) tumors implanted in the flanks of NOD/SCID mice. Tumor-bearing mice were treated with vehicle or 40 mg/kg NXP900 daily for up to 4 weeks. To identify factors associated with response, a multiomic approach was used, integrating RNA-Seq, global proteomics, and phosphoproteomics. A hierarchical-all-against-all algorithm (HallA) assessed associations between multiomic features and drug response in tumor growth. Kinase enrichment analysis (KEA3) identified features linked to sensitivity or resistance. Results: HuCCT1-R cells showed increased pTyr abundancy of TNK2, a protein known to increase PIP3 levels leading to AKT activation, and of DYRK3 and LAMTOR1, both of which can sustain AKT phosphorylation via mTORC, indicating acquired resistance through bypassing inhibited PI3K-AKT signaling to rescue AKT. NXP900 reduced tumor growth rates in 5 of 9 PDX models. Kinases associated with sensitivity in the PDX models included SFKs (SRC, LYN, and FYN), and AKT, PTK2, PRKCZ, EGFR, SYK, and GSK3B, suggesting involvement of the PI3K-AKT pathway in responsiveness to NXP900. Based on tumor inhibition responses in the tested models, we estimated NXP900 response for our additional PDX models, predicting 39% (11/28) of patient tumors may respond. Conclusion: This study identified molecular markers linked to response to SFK inhibition, which could be utilized for patient selection for NXP900 treatment. Further studies are validating these findings and exploring combination therapies to address resistance mechanisms. Citation Format: Hendrien Kuipers, Danielle M. Carlson, Jack W. Sample, Erik Jessen, Dong-Gi Mun, Aushinie M. Abeynayake, Jennifer L. Tomlinson, Amro M. Abdelrahman, Nathan W. Werneburg, Binbin Li, Mitesh J. Borad, Mark J. Truty, Sumera I. Ilyas, Gregory J. Gores, Rory L. Smoot. Multiomic profiling identified biomarkers of response to selective Src family kinase inhibition in preclinical models of cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5595.
Abstract 2335: Predicting cirrhosis risk in patients with metabolic dysfunction-associated steatotic liver disease
Sherpa, Pasang , Armasu, Sebastian M. , Frank, Jacob A., Antwi, Samuel O. , Antwi, Samuel O , Wangensteen, Kirk J , Sherpa, Pasang, Yan, Irene K. , Wangensteen, Kirk J. , Patel, Tushar P

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2335-2335

10.1158/1538-7445.am2025-2335 Get It

Abstract Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 32% of adults worldwide and is projected to increase in many parts of the world. Liver cancer is a recognized complication of end-stage MASLD. An estimated 20% of patients with MASLD will progress to cirrhosis, a premalignant state in liver cancer evolution. Because MASLD is usually asymptomatic, its progression to cirrhosis can be difficult to detect early for timely intervention. There are currently no known biological markers for predicting cirrhosis risk in patients with MASLD, making it challenging to identify patients at risk of disease progression. The aim of this study was to identify plasma protein biomarkers that can predict future cirrhosis development in patients with MASLD. Methods: We performed a nested case-control study among patients with MASLD at baseline who later progressed to cirrhosis and control patients with MASLD at baseline who never progressed to cirrhosis, matched on age at MASLD diagnosis (± 1-year), sex, race, year of blood sample collection, and length of follow-up (± 1-year). An aptamer-based array (SOMAscan™) platform was used to measure over 7000 proteins in baseline plasma samples obtained from the participants. The study sample was split 70/30 for training and validation analyses. We identified plasma protein biomarkers significantly differentially expressed in the training sample, adjusting for multiple testing with Bonferroni-corrected p-values. The significant set of proteins from the training set was used for prediction modeling in the validation sample, computing prediction metrics (area under the curve [AUC], sensitivity, specificity, and accuracy). Results: A total of 64 MASLD to cirrhosis cases matched to 64 MASLD controls were included in the analysis. Six protein biomarkers (PTPRU, ATL2, MFAP4, C7, CSTN2, and COLEC11) were overexpressed in cases, compared to controls, in the training data. Prediction modeling of the six-protein biomarker panel in the validation sample yielded an AUC = 0.85, sensitivity = 0.72, specificity = 0.78, and accuracy = 0.75. Conclusions: We have identified a panel of six plasma protein biomarkers that predict risk of cirrhosis development in patients with MASLD. These proteins could serve as candidates for future mechanistic studies on MASLD progression to advanced liver disease. If validated in larger studies and with assays suitable for clinical laboratory testing (e.g., ELISA), these protein biomarkers could be useful clinically for cirrhosis risk prediction in MASLD patients, and hence those at risk of liver cancer, enabling timely surveillance or interventions to prevent disease progression. Citation Format: Pasang Sherpa, Sebastian M. Armasu, Jacob A. Frank, Irene K. Yan, Kirk J. Wangensteen, Tushar Patel, Samuel O. Antwi. Predicting cirrhosis risk in patients with metabolic dysfunction-associated steatotic liver disease [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2335.
Abstract 5915: Real world clinical characteristics of claudin 18.2 expression in patients with pancreatic adenocarcinoma
Kerper, Allison , Getzenberg, Robert H. , Kerper, Allison L. , Graham, Rondell P.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5915-5915

10.1158/1538-7445.am2025-5915 Get It

Abstract Background: Pancreatic cancer is a frequently fatal disease that is often diagnosed at a late stage associated with a poor prognosis and an increasing impact on cancer related mortality. Despite advances, chemotherapy remains the mainstem of therapeutic interventions for this disease and most of the currently identified molecular alterations are not currently targetable. Therefore, novel biomarkers and strategies are necessary to impact patient outcomes. Claudin-18.2 (CLDN18.2) is a splice variant of the Claudin 18 family and is a component of tight junctions, which seal the paracellular spaces of epithelial and endothelial cells. CLDN18.2 is frequently retained in malignant gastric tissue and overexpressed in pancreatic and gastroesophageal adenocarcinomas. CLDN18.2 overexpression at the message and protein levels has been observed in pre-clinical studies involving pancreatic cancer cell lines and in tumors from pancreatic cancer patients. The goal of this study was to obtain a deeper understanding of CLDN18.2 positivity and CLDN18.2 expression and the associated clinical prevalence, prognostic implications, patient clinical characteristics and relationship with other biomarkers in pancreatic ductal adenocarcinoma (PDAC) patient samples. Design: This was a single institution/reference laboratory based retrospective study including as many as 320 patients, in which CLDN18.2 positivity as defined by ≥ 75% of the tumor cells expressing moderate to strong membranous staining was examined. The goals were to evaluate CLDN18.2 in tumor samples by immunohistochemistry for prevalence in pancreatic adenocarcinoma patients. Claudin 18.2 expression was assessed by the Ventana (43-14A) Class I IVD that was purchased from Ventana/Roche Diagnostics. In addition to prevalence, CLDN18.2 was evaluated with respect to the clinicopathological features of patients, patient prognosis, adjusted for clinical covariables, response to treatments and relationship to patient demographics, tumor grade and disease status. Patient information has been obtained from electronic medical records and research database to establish clinical course (survival status, metastatic sites, etc.) along with patient demographics. Conclusions: CLDN18.2 is a novel potentially actionable biomarker in patients with advanced and metastatic pancreatic adenocarcinoma. This study provides important clinical information regarding CLDN18.2 expression in these patients that is important to consider when evaluating biomarkers in these patients. Funding for the study was provided by Astellas Pharma Global Development, Inc. Citation Format: Allison Kerper, Robert H. Getzenberg, Rondell P. Graham. Real world clinical characteristics of claudin 18.2 expression in patients with pancreatic adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5915.